Trade Summary

2 days ago, Halladay Benjamin, serving as Chief Financial Officer at Esperion Therapeutics, Inc. (ESPR), sold 10,773 shares at $3.15 per share, for a total transaction value of $33,988.81. Following this transaction, Halladay Benjamin now holds 702,829 shares of ESPR.

This sale represents a 1.51% decrease in Halladay Benjamin's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, June 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, June 18, 2026 at 4:05 PM ET, 1 day after the trade was made.

Esperion Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.